Latest News

130919

Athera elects new Chairman of the Board and moves to new premises

STOCKHOLM, SWEDEN –Sept 19, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.

The extraordinary shareholders meeting in Athera has elected Gunnar Olsson new Chairman of the Board after Per Sjöberg, who has been leading the company for eight years. Dr Olsson joins Athera after 24 years in AstraZeneca, where he has held several senior management positions, mainly within therapy area leadership for cardiovascular and gastrointestinal disease. He holds an MD and PhD from Karolinska Institutet and is specialist in Cardiology and Internal Medicine. Dr Olsson is Honorary Doctor of Medicine at Gothenburg University.

Tomas Odergren, MD, PhD and specialist in Neurology, joined the Board of Directors at the Annual General Meeting in June, and he brings an excellent and well-timed expertise in clinical development. Otto Skolling remains on the Board, while Paul de Potocki and Per Sjöberg resign.

“I am very pleased to hand over to a Chairman with such strong experience from industrial drug development and business” says Per Sjöberg. “Gunnar has an extensive international network and expertise in cardiovascular drug development, and both he and Tomas will be able to make great contributions to the next development phases in Athera.”

The company has recently moved their office to new premises at Business Center on Sankt Eriksgatan 117 in Stockholm, next to Hagastaden and the new Karolinska Hospital.

About Athera Biotechnologies AB Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in late preclinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera has an exclusive option agreement with Boehringer Ingelheim. Karolinska Development AB (publ) owns 65% of Athera Biotechnologies AB.

For more information, please visit www.athera.se.

For further Information: Carina Schmidt, Chief Executive Officer, Athera Biotechnologies AB Tel: +46 76 193 81 90 E-mail: c.schmidt@athera.se

130823

Athera and Medirista sign agreement to transfer the Annexin A5 project

STOCKHOLM, SWEDEN – Aug 23, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB. Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård. The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.

Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery. Annexin A5 has been shown to beneficially affect remodelling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice. Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.

About Athera Biotechnologies AB

Athera has a unique and in-depth understanding of the immunological components in

atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in late preclinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera has an exclusive option agreement with Boehringer Ingelheim. Karolinska Development AB owns 65% of

Athera Biotechnologies AB. For more information, please visit www.athera.se.

For further Information:

Carina Schmidt, Chief Executive Officer, Athera Biotechnologies AB

Tel: +46 76 193 81 90

E-mail: c.schmidt@athera.se

130619

Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy

for Atherosclerosis

STOCKHOLM, SWEDEN – June 19, 2013. Athera Biotechnologies AB today announced that it has entered into an option agreement with Boehringer Ingelheim International GmbH on a novel preclinical antibody program, whereby Athera grants to Boehringer Ingelheim an exclusive option to acquire the entire program. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

Athera’s fully-human monoclonal antibody is intended for the treatment of patients with

cardiovascular disease, who are at an increased risk of secondary events and death.

Pursuant to the terms of the option agreement, Athera will conduct defined preclinical development and a Phase I study for the lead antibody and, following the completion of such study, Boehringer Ingelheim will have an exclusive option to acquire substantially all of Athera’s assets and rights relating to the program. In exchange for Athera’s granting of the option, Boehringer Ingelheim will pay an option fee. The size of the fee and the other terms of the option are not being disclosed but this transaction is in line with market average terms for programs at similar stages of development.

"We are proud that Athera's research has attracted a top tier company to enter an option agreement of this magnitude and we are confident that Boehringer Ingelheim, with its vast experience and resources within the cardiovascular field, is the ideal partner for this innovative program", said Torbjörn Bjerke, CEO and President at Karolinska Development.

“The option agreement with Boehringer Ingelheim is an important validation of the quality in Athera’s cardiovascular antibody program and together with the recently announced EU grant we have now secured financing through Phase I clinical trials and the potential exercise of the option agreement”, said Carina Schmidt, CEO of Athera Biotechnologies.

For further information, please contact:

Torbjörn Bjerke, CEO, Karolinska Development AB

Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com

Carina Schmidt, CEO, Athera Biotechnologies AB

Phone: +46 (0) 76 193 81 90 e-mail: c.schmidt@athera.se

Benjamin Nordin, IRO, Karolinska Development AB

Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Athera Biotechnologies AB

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, PC-mAb, is in late preclinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker,

anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.

For more information, please visit www.athera.se.

About Karolinska Development AB

Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 15 are in clinical development. For more information, please

visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

130617

EU grants EUR 6m to the clinical development of Athera´s cardiovascular disease antibody therapy

STOCKHOLM, SWEDEN – June 17, 2013. Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death. This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.

“The grant underpins the level of innovation of the PC-mAb project and will substantially contribute to the pace of the future development”, comments Torbjörn Bjerke, CEO of Karolinska Development.

The EUR 6m grant has been provided to the CARDIMMUN consortium, consisting of Athera, Leiden University Medical Center (LUMC), Turku PET Center (Turku University), Clinical Trial Consultants (CTC) and Smerud Medical Research. The project has a total budget of nearly EUR 8m and will be running over three years, focusing on key preclinical activities and clinical trials aimed at demonstrating proof-of-concept of this new cardiovascular treatment. LUMC is the project coordinator and will be leading

the project together with Athera.

“I am very pleased that Athera is part of the CARDIMMUN consortium and thereby receives support from the FP7. With this non-dilutive funding, Athera will be able to take its proprietary monoclonal antibody PC-mAb through major milestones”, says Carina Schmidt, CEO of Athera Biotechnologies.

For further information, please contact:

Torbjörn Bjerke, CEO, Karolinska Development AB

Phone: +46 (0)72 744 41 23, email: torbjorn.bjerke@karolinskadevelopment.com

Carina Schmidt, CEO, Athera Biotechnologies AB

Phone: +46 (0)76 193 81 90, email: c.schmidt@athera.se

Benjamin Nordin, IRO, Karolinska Development AB

Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Athera Biotechnologies AB

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, PC-mAb, is in late preclinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. Low levels of the biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the

future be used for identification of patients that benefit from Athera’s novel therapeutics. For more information, please visit www.athera.se.

About Karolinska Development AB

Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the

greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 15 are in clinical development. For more

information, please visit www.karolinskadevelopment.com.

About PC-mAb

Naturally occurring antibodies to phosphorylcholine (anti-PC) have anti-inflammatory properties and prevent the uptake of oxidized LDL in macrophages. So does PC-mAb from Athera, a unique fully human monoclonal antibody developed for Athera by Dyax Corp. in Boston, USA, and which is currently in late pre-clinical development. PC-mAb is aimed at restoring cardio-protective levels of anti-PC and thereby preventing secondary CVD events.

About FP7

FP7 (7th Framework Programme for Research and Technological Development) is a key tool for the European Commission to respond to Europe's needs in terms of jobs and competitiveness, and to maintain leadership in the global knowledge economy. The programme has a total budget of over EUR 50bn, which will (for the most part) be spent on grants to research activities all over Europe and beyond, in order to co-finance research, technological development and demonstration projects. Grants are determined on the basis of calls for proposals and a peer review process, which are highly competitive.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

121025

Low levels of anti-PC predict vein graft failure

STOCKHOLM, SWEDEN – October 25, 2012. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that results from a new study

were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine® kit, are associated with a high risk for vein graft failure after bypass surgery.

It is known from previous published studies that low plasma levels of antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients,

as well as to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke in healthy individuals. Professor Michael Sobel of the Division of Vascular Surgery, VA Puget Sound HCS and the University of Washington, Seattle, USA, and his colleagues have now conducted a pilot, prospective, observational study in patients undergoing vein bypasses for atherosclerotic occlusive disease of the legs.

The objective of the study was to determine if low anti-PC antibody levels might be associated with loss of primary patency. Measurements of anti-PC levels in these

patients, using a simple blood-test, showed that low levels were associated with a high risk of thrombosis or re-intervention for stenosis, also raising the possibility of treatment with immunotherapies to improve bypass longevity. The testing was performed using Athera’s CVDefine® kit.

More than one in four of all vein graft procedures develop stenosis or fail within the

first 1-2 years. These patients are at risk for re-intervention, as well as more serious complications like leg amputation or death. Current treatments to improve graft longevity are limited to general medical treatments

(e.g. antithrombotic drugs and lipid lowering agents) or procedures to revise the graft, but no targeted treatments are approved yet.

Carina Schmidt, CEO of Athera: “Athera is developing an anti-inflammatory antibody therapy, PC-mAb, for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC. These new findings may open

opportunities for PC-mAb and its companion diagnostic kit CVDefine®, for identification and treatment of a high-risk patient group in a niche indication of high medical need.”

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, PC-mAb, is in late preclinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore vascular and cardio-protective levels of anti-PC and prevent secondary CVD events. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. For more information, please visit www.athera.se.

For further Information:

Athera Biotechnologies AB (publ)

Chief Executive Officer

Carina Schmidt

Tel +46 76 193 81 90 c.schmidt@athera.se

120302

Annexin A5 at low doses prevents atherosclerosis –

Study published in Atherosclerosis

Solna, Sweden, March 2nd, 2012 –Treatment with low doses of recombinant Annexin A5 prevents vascular remodelling in a preclinical study. These results were recently published in an article in Atherosclerosis.

Patients who undergo common surgery for cardiovascular disease are at risk for inflammation-driven complications after the intervention. It has previously been shown that Annexin A5 beneficially affects remodelling in a preclinical model of coronary bypass grafting.

This study showed that Annexin A5 could prevent injury induced accelerated atherosclerosis and thickening of the vascular intima, in a model mimicking catheter-based percutaneous interventions (PCI) in mice. The results confirm that the anti-inflammatory effect of recombinant Annexin A5 could be seen in doses 3-10 times lower than previously investigated. PCI has become a gold standard in rapidly treating patients with acute heart attack. Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.

“These recently published findings support our approach to develop recombinant Annexin A5 as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery. We have successfully developed a cost-effective manufacturing process which has been transferred to the cGMP facility and we are now actively discussing co-development opportunities for further preclinical and clinical studies", says Carina Schmidt, CEO of Athera.

120207

Study linking outcome in acute coronary syndromes to anti-PC published in

International Journal of Cardiology

Solna, Sweden, February 7th, 2012 – Scientists conclude that measuring antibodies to phosporylcholine (anti-PC), using a simple blood-test, may provide important and independent information on the prognosis of heart attack patients, in a study just published on-line in International Journal of Cardiology. The testing was performed using Athera Biotechnologies CVDefine® kit.

Already published studies have reported that low levels of anti-PC in healthy individuals are linked to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke. This study measured anti-PC levels in samples from 1185 acute coronary syndrome (ACS) patients and shows for the first time that low anti-PC levels indicate poor prognosis in these patients, with a high risk for new cardiovascular events and even death. The scientists suggest that low levels of anti-PC might give an insufficient protection to counteract vascular inflammation and the risk of plaque rupture. Low anti-PC levels may therefore represent a new paradigm for reporting reduced atheroprotection in heart disease and identify patients in need of more

intense treatment to prevent secondary events.

“We are in active development of an anti-inflammatory antibody therapy for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC. These new findings strengthens the therapeutic approach with a companion diagnostics potential and suggests that increasing anti-PC levels in these patients could have a beneficial effect on outcomes", says Carina Schmidt, CEO of Athera

111111

Athera Forms New Scientific Advisory Board

– Professors Libby, Simoons, Wallentin and de Faire join

Solna, Sweden, November 11th, 2011 – Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the new Scientific Advisory Board is formed, including professors Peter Libby, Maarten Simoons, Lars Wallentin, and Ulf de Faire.

"We are very pleased to welcome four well-respected medical experts in CVD research as new members of the Scientific Advisory Board," says Per Sjöberg, Chairman of the Board in Athera Biotechnologies " Their tremendous knowledge in cardiovascular disease, vascular inflammation, biomarkers and new treatment approaches is very valuable to Athera, as our projects now are advancing towards the clinic."

Dr Peter Libby is the chief of cardiovascular medicine at Brigham and Women's Hospital and Mallinckrodt Professor of Medicine, Harvard Medical School, both in Boston, USA.

His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments. His areas of clinical expertise include general and preventive cardiology.

Dr Maarten Simoons is Professor of Cardiology (emeritus) and was Chief of Cardiology, at the Thoraxcenter, Erasmus University Medical Center in Rotterdam, the Netherlands. His research interests include acute and chronic ischemic heart disease, as well as information technology and pharmacogenetics. He was a member of the Board of the European Society of Cardiology and president of the Society 2000-2002. He is a member or the Royal Netherlands Academy of Arts and Science (KNAW).

Dr Lars Wallentin is Professor of Cardiology (emeritus) at the Department of Medical Sciences, Uppsala University Hospital and founder of Uppsala Clinical Research Center (UCR). Over the last 20 years professor Wallentin has been the chairman and principal investigator of many national and international clinical trials of new treatment concepts in cardiac diseases. His group has pioneered the use of molecular biomarkers and new treatments concepts in acute coronary artery diseases.

Dr Ulf de Faire is Professor of Cardiovascular Epidemiology (emeritus) at the Institute of Environmental Medicine, Karolinska Institute, Solna, Sweden. He is active in research on mechanisms and risk factors, involved in the development of atherosclerosis and cardiovascular diseases, and with particular emphasis on genetic mechanisms and biomarkers. Professor de Faire is a scientific founder of Athera.

110823

Athera Receives Allowance of Key Patent for CVD Antibody Therapy

Solna, Sweden, August 23th, 2011 – Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the US Patent Office intends to grant a key patent related to the Company's intellectual property covering its therapeutic antibody candidate PC-mAb. Following subsequent grant, the patent will provide strong protection for pharmaceutical uses of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular diseases. The corresponding European and Australian patents have already been granted and further applications are pending worldwide.

"This US patent strengthens our efforts in building an attractive and competitive pharmaceutical product portfolio in cardiovascular disease," says Carina Schmidt, Athera Biotechnologies CEO. "I am convinced that PC-mAb has the potential to develop into a medicine that will fulfill important medical needs. We can see this also in a great interest from the pharmaceutical industry to explore partnering opportunities with Athera for future clinical developments."

110530

Study mapping genetic and environmental links of anti-PC published in Atherosclerosis

Solna, Sweden, 30 May 2011 – Scientists suggest an independent role of anti-PC as a biomarker in cardiovascular disease in a study just published on-line in Atherosclerosis. Atherosclerosis. The testing was performed using Athera Biotechnologies CVDefine® kit.

Previous studies have reported that low levels of anti-PC are linked to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke. This study measured anti-PC levels in samples from 2036 elderly twins, with an observed heritable component of 40 %. This may help to explain the strong genetic impact on cardiovascular risk.

“We are already developing a therapeutic antibody for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC. These new findings indicate that the novel biomarker anti-PC can provide information on atherosclerotic progression not already captured by other established biomarkers", says Carina Schmidt, CEO of Athera

110505

Athera to present at AngloNordic Biotech Conference in London

London, United Kingdom, 5 May 2011 – Athera CEO Carina Schmidt is today an invited speaker at the AngloNordic Biotech Conference. The Anglo-Nordic region continues to be one of the fastest growing biotech regions in the world. Now entering the eighth year, the Anglonordic Biotech Conference provides an opportunity to meet contributors to this success. The audience is invited professionals of pharmaceutical companies and venture capital firms. Ms Schmidt will present the investment opportunity Athera, part of Karolinska Development AB (publ) portfolio, in the Aescap Venture Investment Room.

110428

Athera presents at the first International Pharmacy Engineering and Biotechnology

Forum in St. Petersburg

St. Petersburg, Russia, 28 April 2011 – Athera CEO Carina Schmidt is one of the invited speakers at the first international business forum IPhEB, dedicated to establishment of a pharmaceutical cluster in St. Petersburg. Ms Schmidt will build on experiences from development of the emerging biotech company Athera, part of Karolinska Development AB (publ) portfolio- from early innovation stages to product development and commercialization - to discuss issues around the topic “From Innovation to Business – Challenges and Rewards”. The IPhEB business event is planned to be participated by over 300 delegates from 200 companies – government authorities, top managers and experts of the Russian and international pharmaceutical and biotechnological enterprises, and representatives of scientific research centers and institutes. Speakers include Evgeny Zaytsev, Director General, Helix Ventures, Dr. Jonas Brambeck, Investment Manager Industrifonden, Dr. Bo-Ragnar Tolf, Director, Innovation Office, Karolinska Institutet, G. Steven Burrill, Director General, Burrill & Company and many other leading specialists of the industry.

Member of

Events

Member of

Press Room

Logos

Carina Schmidt, CEO Photo: L. Skog

Lab use of CVDefine kit.

Person is Dr. Helen Lettesjö Photo: A. Aronsson

Pharma pre-clinical development lab. Persons are Drs. Knut Pettersson VP Pre-clinical development and Mariette Nordzell, Senior Scientist Photo: L. Skog

Member of

News Archive

110317

Emerging Biotech Company Athera and Lonza Sign Development and Manufacturing Agreement

•The agreement secures a development and cGMP manufacturing plan for Athera Biotechnologies, part of the Karolinska Development portfolio

•Lonza will initiate cell line and process development, using Lonza’s GS Gene Expression SystemTM

•Athera’s monoclonal antibody, PC-mAb, is intended for the treatment of patients with Acute Coronary Syndrome who are at an increased risk of secondary cardiovascular events and death

Basel, Switzerland, 17 March 2011 – Athera and Lonza announced today a new development and manufacturing agreement. Lonza will initiate cell line and process development for Athera’s monoclonal antibody PC-mAb. Athera’s PC-mAb is intended for the treatment of patients with Acute Coronary Syndrome who are at an increased risk of secondary cardiovascular events and death.

This agreement secures a development and cGMP manufacturing plan for Athera. Lonza will initiate cell line and process development, using Lonza’s GS Gene Expression SystemTM.

“Lonza is pleased to continue our support of emerging biotech companies with this commitment to Athera’s promising pipeline,” said Stephan Kutzer, Head of Lonza’s Custom Manufacturing Division. “The PC-mAb project from Athera fits well with Lonza’s core competencies and technical experience.”

“We are very confident with Lonza as our development partner,” said Carina Schmidt, CEO of Athera Biotechnologies. “They have an excellent track record in the field of monoclonal antibody development.”

About PC-mAb

Naturally occuring antibodies to phosphorylcholine (anti-PC) have anti-inflammatory properties and prevent the uptake of oxidized LDL in macrophages. PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody developed for Athera by Dyax Corp. in Boston, USA. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach. Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio. www.athera.se

About Karolinska Development AB (publ)

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties.

An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.

Karolinska Developments flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients - this being an important value enhancing step.

Today, the portfolio consists of over 40 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials with six in Phase II. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system. www.karolinskadevelopment.com

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

For further Information:

Athera Biotechnologies AB (publ)

Chief Executive Officer

Carina Schmidt

Tel +46 761938190

c.schmidt@athera.se

Lonza Group Ltd

Corporate Communications Investor Relations Media Relations

Dominik Werner Dirk Oehlers Melanie Disa

Tel +41 61 316 8798 T +41 61 316 8540 +1 201 316 9413

dominik.werner@lonza.com dirk.oehlers@lonza.com melanie.disa@lonza.com

100908

New Board of Directors in Athera (Only in Swedish)

Ny styrelse i Athera

Athera Biotechnologies har på en extra bolagsstämma valt ny styrelse. Sverker Ljunghall, Akbar Seddigh och Paul de Potocki är nya ledamöter intill nästa bolagsstämma. Athera Biotechnologies är ett av Karolinska Developments portföljbolag.

Per Sjöberg, styrelseordförande i Athera:

”Jag är mycket glad över att vi får arbeta med de nya ledamöterna, som tillför betydande industrierfarenhet. Deras kontaktnät inom kardiologi, till investerare och möjliga licenspartners, samt deras kompetens inom läkemedelsutveckling ger oss utmärkta möjligheter att förbereda bolaget för nästa utvecklingsfas.”

Antalet styrelseledamöter utökas i och med denna stämma från nuvarande 6 till 7. Otto Skolling, Per Sjöberg, Tore Mellstrand och Jan Würtz kvarstår i styrelsen. De tidigare styrelseledamöterna Johan Frostegård och Ulf de Faire utträder ur styrelsen. Frostegård och de Faire, som även är vetenskapliga grundare och verksamma som professorer på Karolinska Institutet, kommer att vara fortsatt engagerade som vetenskapliga rådgivare och i bolagets vetenskapliga råd.

Sverker Ljunghall är läkare och professor emeritus i medicin vid Uppsala Universitet. Närmast före pensionen har Ljunghall arbetat drygt 10 år inom AstraZeneca, bland annat som global chef för klinisk utveckling.

Akbar Seddigh har en stor erfarenhet från styrelsearbete i noterade bolag inom medicinsk forskning och utveckling. Bland andra uppdrag är Seddigh styrelseordförande i Elekta AB (publ), styrelseordförande i Innovationsbron AB och Blekinge Högskola, vice styrelseordförande i Sweden Bio (branschorganisation för bioteknisk forskning).

Paul de Potocki har haft ett flertal positioner inom global försäljning och strategisk marknadsföring på Pharmacia, Fresenius, Kabi och inom Unileverkoncernen. Han har bland annat varit direktör för global strategisk marknadsföring på Fresenius Kabi och vice VD, strategisk marknadsföring och försäljning på Pharmacia. De Potocki har tidigare arbetat med Biovitrum AB där han hade en tjänst som direktör för kommersiell och strategisk utveckling och varit medlem av företagsledningen. Han är idag VD för Aerocrine AB (publ) som han var med och introducerade på NASDAQ OMX.

För ytterligare information kontakta:

Carina Schmidt, VD Athera Biotechnologies AB

Telefon : 070-552 5115

E-post: c.schmidt@athera.se

TILL REDAKTIONEN

Om Athera Biotechnologies AB (publ)

Athera är ett bioteknikföretag med unik kompetens kring immunologiska orsaker till åderförkalkning, den inflammatoriska process som leder till hjärtkärl-sjukdom. Bolaget har idag två biologiska läkemedelskandidater för att behandla patienter med hjärtinfarkt och en biomarkör som är kopplad till behandlingen. Athera är ett portföljbolag inom Karolinska Development AB (publ). www.athera.se

Om Karolinska Development AB (publ)

Karolinska Development förvaltar en av de största portföljerna med life science-företag i Europa. Genom en unik affärsmodell kan bolaget kostnadseffektivt styra kommersialiseringen av life science-innovationer i världsklass. Sedan starten 2003, har Karolinska Development byggt upp en portfölj av ett 40-tal bolag. Bland bolagens projekt befinner sig 12 läkemedelskandidater i klinisk utvecklingsfas och totalt bedöms mer än 20 substanser ha "first-in-class"-potential. www.karolinskadevelopment.com

100827

Athera signs distribution agreement in Scandinavia

Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.

Carina Schmidt, VD i Athera: "This is an important step in the broader commercialization of CVDefine. Together with Electra-Box we will now be able to expand our contacs with leading clinial scientist in the cardiovascular field and increase the exposure of our trademark. We look forward to be able to work with the experienced Electra-Box team."

Peter Blom, responsible for clinical chemistry in Electra-Box Diagnostica: "We are very excited about the opportunities this agreement present. This will allow us to offer a new CVD biomarker to customers in Scandinavia. Since CVDefine® may add important and independent information in cardiovascular risk assessment; we believe there is a lot of interest from scientist in the field to generate further clinical research data".

High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be cardio-protective. Low levels of anti-PC are known to be involved in atherosclerosis development and increased risk for acute cardiovascular events, like stroke and myocardial infarction. Athera is investigating the possibilities to develop new immunological therapies to prevent secondary cardiovascular events and to identify the patients who benefit most from this treatment with CVDefine, and consequently contribute to better care after acute heart disease.

For additional information, please contact:

Carina Schmidt, CEO Phone: +4670-552 5115 E-mailt: c.schmidt@athera.se

TO THE EDITORS

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is part of the Karolinska Development AB (publ) portfolio. www.athera.se

About CVDefine

CVDefine® is a diagnostic test measuring IgM anti-bodies against phosphorylcholine (anti-PC). Low levels of anti-PC indicate a risk for future development of cardiovascular disease (CVD). CVDefine® is an ELISA kit for early detection of increased cardiovascular risk due to atherosclerosis and vascular inflammation.

About Karolinska Development (publ)

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. www.karolinskadevelopment.com

About Electra-Box Diagnostica AB

Electra-Box Diagnostica is a distribution company for products to research and clinical laboratories in Sweden, Denmark, Norway, Finland and Baltic countries. www.electrabox.com

100629

Study links anti-PC to Alzheimer´s disease

Scientist show doubled prevalence of Alzheimer`s disease in patients with low levels of anti-PC in a study just published in Journal of Alzheimer´s Disease. The testing was performed using Athera Biotechnologies CVDefine® kit.

"Previous studies have established that high levels of anti-PC are linked to decreased risk of atherosclerosis. It has also been reported that low levels of anti-PC contribute to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke. We are already developing theraputic antibody candidates for prevention of secondary cardiovascular event after myocardial infarction, says Carina Schmidt, CEO of Athera. These new findings indicate that there may be other serious diseases where immunological treatments may be of interest."

For further information:

Carina Schmidt, VD Athera Biotechnologies AB

Telefon : 070-552 5115

E-post: c.schmidt@athera.se

100215

Low levels of natural antibodies behind stroke

The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The research group, which was led by Professor Johan Frostegård, has previously demonstrated that high levels of a certain type of antibody (anti-PC) in the immune defence are linked to a reduced risk of arteriosclerosis, a common cause of thrombosis and myocardial infarction.

In the present study, the researchers focused exclusively on stroke - a blood clot in the brain - and compared 227 individuals who had suffered stroke over a 13-year period with 445 sex and age-matched controls. After controlling for other risk factors (age, sex, smoking habits, cholesterol levels, diabetes, BMI and blood pressure), they were able to show that low levels (below 30 per cent of average) of PC antibodies correlated with a higher risk of stroke, which in women meant an almost three-fold increase.

Natural antibodies to phosphorylcholine (PC) are known to be cardio-protective and are antibodies to specific surface regions on OxLDL. High levels of antibodies against PC (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients. Later data from several studies confirm that low anti-PC levels predict an increased risk of CVD and even are linked to increased mortality in Acute Coronary Syndrome patients. The pharmaceutical product candidate, PC-mAb, is developed by Athera in collaboration with Dyax Corp. in Boston, USA (NASDAQ:DYAX). The biomarker product CVDefine®, that has the potential to enable a “theranostics” approach in prevention of cardiovascular disease, is on the market and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.

Contact:

Carina Schmidt, CEO Phone: +46 70 552 5115 Mail: c.schmidt@athera.se

091014

Athera Receives Allowance of Two Key Patents

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

Following subsequent grant the patents will be registered in the designated European countries, and there are corresponding patent applications pending worldwide. Together, the patents will provide strong protection for pharmaceutical uses of Annexin A5 for the prevention of plaque rupture, as well as use of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular disease.

"These European patents strengthens our efforts in building an attractive and competitive pharmaceutical product portfolio in cardiovascular disease," said Carina Schmidt, Athera Biotechnologies Chief Executive Officer. "I am convinced that the product candidates that Athera develops have the potential to fulfil important medical needs. We can see this also in a great interest from the pharmaceutical industry to explore partnering opportunities with Athera for future clinical developments."

Natural antibodies to phosphorylcholine (PC) are known to be cardio-protective and are antibodies to specific surface regions on OxLDL. High levels of antibodies against PC (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients. Later data from several studies confirm that low anti-PC levels predict an increased risk of CVD and even are linked to increased mortality in Acute Coronary Syndrome patients. The pharmaceutical product candidate, PC-mAb, is developed by Athera in collaboration with Dyax Corp. in Boston, USA (NASDAQ:DYAX). The biomarker product CVDefine®, that has the potential to enable a “theranostics” approach in prevention of cardiovascular disease, is on the market and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

Athera’s second novel product candidate, Annexin A5, is developed for prevention of plaque rupture and athero-thrombosis through binding of the protein to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction. Athera has an agreement with Richter-Helm BioLogics GmbH & Co. KG in Hamburg, Germany, for the process development of the product.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.

Contact:

Carina Schmidt, CEO Phone: +46 70 552 5115 Mail: c.schmidt@athera.se

090924

Athera and ALPCO sign distribution agreement in North America.

Sean Conley, COO of ALPCO, said “We are very excited about the opportunities presented by this agreement, which will enable us to offer a new CVD biomarker to customers in North America. CVDefine® may add important and independent information in cardiovascular risk assessment and we believe there is a lot of interest from scientist in the field to use this to generate further clinical research data”.

High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients after a five-year follow up. However, in 2008 data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine, was introduced last year and provides an easy-to-use ELISA kit (Research Use Only) for quantitative analysis of anti-PC in human blood. A CVDefine CE-marked kit is available in Europe.

“This distribution agreement is another important step for Athera as we expand in the North American market. This agreement broadens our presence and increases the exposure of our trademark. I am pleased with the opportunities this represents and I look forward to working with the efficient and experienced team from ALPCO”, says Carina Schmidt, CEO Athera Biotechnologies AB.

About ALPCO

ALPCO (American Laboratory Products Company) was founded in 1990 as an importer and distributor of high quality research immunoassay kits. In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays. Much of this successful growth can be attributed to the ongoing communication and collaborative relationships with customers and respected thought leaders in the academic, biotech and clinical arenas.

www.alpco.com

Contact:

Carina Schmidt, CEO Phone: +46 70 552 5115 Mail: c.schmidt@athera.se

090429

Cardiovascular and Alzheimer therapy project wins VINNOVA grant

The Swedish Governmental Agency for Innovation Systems, VINNOVA, has granted support to Athera Biotechnologies and Karolinska Institutet for development of antibodies for treatment of cardiovascular and Alzheimer diseases. Athera is an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), which currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach.

Four hundred fifty applicants had responded to the first call of the program called “Innovations for future health”, for a total amount of SEK 3,900 million. VINNOVA has today announced the 17 projects and 6 research and innovation clusters supported with over SEK 200 million. The project including Athera Biotechnologies and Karolinska Institutet scientists is among the winners, with a budget of SEK 5 million over three years. The project includes activities to further develop the understanding of natural antibodies to phospholipids, including anti-PC, in several inflammatory conditions, where an under-active immune defense decreases the protection to oxidized phosholipids.

Last year, data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine®, was introduced last year and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

Through the “Innovations for future health” program, VINNOVA finances research and innovation projects developing novel products for prevention, diagnostics, treatment and care, with a potential to improve health within 10-15 years. In the next five years a total of up to SEK 600 million will be granted in several calls.

090416

Athera signs agreements with German and UK distributors for new cardiovascular biomarker.

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that it has signed two distributor agreements - with Asbach Medical Products GmbH and with Oxford Biosystems Ltd.

Carina Schmidt, CEO of Athera, said “We are very excited about the opportunities these agreements present to Athera. They will allow us to reach a large number of customers in Germany and UK and will support further development of the broader clinical utility of our new CVD biomarker. We are looking forward to work with the experienced team in Asbach Medical Products and Oxford Biosystems”.

High levels of IgM antibodies against phosphorylcholine (anti-PC) has been shown to predict less atherosclerosis development in hypertensive patients after a five-year follow up. However, in 2008 data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine®, was introduced last year and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

090121

New Partner in Development of Recombinant Protein to Treat Cardiovascular Disease

Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera’s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction.

This agreement secures a highly cost efficient long-term development and manufacturing plan for Athera, including possible future large volume commercial production. Annexin A5 is a biotechnology product produced using Richter-Helm’s proprietary E. coli based expression system. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 litre production scale.

“The Annexin A5 project fits well with the competence and experience of our company. We are confident that our collaboration will be as efficient and constructive as our negotiations were. Our state-of-the-art facilities are ideal for producing the high-quality Annexin A5 required to comply with the standards of the regulatory agencies.”, stated Dr. Bert Behnke, Managing Director of Richter-Helm.

“We are very pleased to get Richter-Helm as our development partner, they have an excellent reputation. We have now secured cost competitive and high quality production for clinical and commercial use”, said Carina Schmidt, CEO of Athera Biotechnologies.

081125

Atherosclerosis vaccine study wins VINNOVA grant

Athera Biotechnologies has been granted support from the Swedish Governmental Agency for Innovation Systems, VINNOVA, for a pre-study to investigate a new approach with vaccination to prevent atherosclerosis. Three hundred companies had applied for the current call to the Research&Growth program to a total amount of SEK 440 million. VINNOVA has today announced the 49 companies of these 300 which are supported with in total SEK 50 million. Athera Biotechnologies is among the seven grant winners who are involved in the life science industry. Through the Research&Growth program, VINNOVA finances research and development projects in small companies. Companies can apply for support for research and development projects, pre clinical trials or necessity identification before research and development projects.

081002

Athera and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

Athera and Dyax Corp. (NASDAQ:DYAX) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration follows the recent publication of work by Athera scientific founders, Professors Frostegård and de Faire of the Karolinska Institutet. During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo animal models for use in selecting a clinical product candidate. Upon successful completion of the discovery work, Athera and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.

“We are very pleased to be working with Athera,” commented Clive Wood, EVP, Discovery Research and CSO of Dyax Corp. “Through their innovative research from the Karolinska Institutet, we believe Athera has identified an exciting potential opportunity for therapeutic antibody treatment of cardiovascular inflammation.”

“The strength of Dyax’s phage display technology, screening capabilities and expertise in drug discovery make them an excellent partner to advance our cardiovascular research program," said Carina Schmidt, CEO of Athera.

080913 Low anti-PC levels predicts CAD severity and outcome in MI patients

Dr Vuilleumier from Geneva University Hospital presented new data on the relevance of anti-PC at the International Autoimmunity Congress in Porto, Portugal.The study included 125 consecutive myocardial infarction (MI) patients who all underwent 6 months follow-up. Endpoints were death, MI, acute coronary syndrome, stroke or acute heart failure requiring hospitalisation. The scientist conclude that low anti-PC IgM levels upon admission in MI is predictive of angiographic CAD severity and poorer cardiovascular outcome at 6 months, independently of traditional cardiovascular factors.

080902 Low levels of anti-PC predict cardiovascular disease

New data presented at the European Cardiology Society Congress in Munich support that low levels of anti-PC IgM predict cardiovascular disease. This confims data from the recently published case-control study in Atherosclerosis. In the studies, a Relative Risk of 1.6 and 1.8, respectively, was indicated when the results were adjusted for smoking, hypertension, lipids, diabetes type II, BMI and hsCRP.

080729 NACB Distinguished Abstract Award at AACC 2008

Athera founder Johan Frostegard of the Karolinska University Hospital

and colleagues win the Award from NACB (National Academy of Clinical Biochemistry) for Distinguished Abstracts at the annual AACC (American Association of Clinical Chemistry) meeting in Washington DC. The abstract "Low levels of IgM Antibodies Against Phosphorylcholine predict incidence of human cardiovascular disease" was one of 26 selected among over 700 accepted abstracts. Winners will be honored at NACB Award luncheon held at the AACC meeting on July 30.

080320 An anti-inflammatory response to vegan diet

Rheumatoid arthritis patients who eat a gluten-free vegan diet could be better protected against heart attacks and stroke. RA is a major risk factor for these cardiovascular diseases, but a gluten-free vegan diet was shown to lower cholesterol, LDL and oxidizedLDL as well as raising the levels of natural antibodies against phosphorylcholine (anti-PC). Johan Frostegard of the Karolinska University Hospital and colleagues divided RA patients randomly into two dietary groups and measured oxLDL and anti-PC at the beginning of the experiment, at 3 months and again at 12 months. The researchers found that the vegan diet not only reduced LDL and oxLDL levels but also raised levels of protective PC antibodies. In contrast, none of the indicators differed significantly for the control groups on the conventional healthy diet.

“Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis- a randomized study” Ann-Charlotte Elkan, Beatrice Sjoberg, Bjorn Kolsrud, Bo Ringertz, Ingiald Hafstrom and Johan Frostegard Arthritis Research & Therapy http://arthritis-research.com/

080306 Presentation at International Hypertension and Stroke Conference

Athera founder Dr. Johan Frostegård from Karolinska Institutet will give a talk on antibodies against phosphocholine as protection factors for atherosclerosis in hypertensive patients at the 2nd International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention. The meeting in Prague, Czech Republic has 1.500 delegates in disciplines from neurology and cardiology to clinical chemistry and epidemiology.

071029 Meet us at MEDICA 2007 World Forum for Medicine Nov 14 - 17 .

Athera exhibits at MEDICA 2007, the worlds greatest trade fair for medtech and healthcare. Nearly 150.000 visitors are expected to come to Dusseldorf to meet with international business contacts. Come to Athera booth in Hall 1, Stand D18. Contact us at info@athera.se to receive an invitation to celebrate the annoucement of our first diagnostic product on Thursday Nov 15 at 2 p.m.

071022 Meet us at American Heart Association (AHA) 2007 Nov 4-6.

Athera Vice President Pre-clinical research, Dr. Knut Pettersson, to participate in AHA annaul meeting in Orlando, Florida. Contact us at info@athera.se to set up a meeting.

071015 Anne-Charlotte Aronsson joins Athera as Vice President Marketing and Sales

Dr Aronsson has more than 25 years experience of the in vitro diagnostic business and has held management positions in business development and international marketing and sales at Pharmacia Diagnostics, Sangtec Medical and DiaSorin SpA. Dr Aronsson has also worked as chief biochemist in a large hospital laboratory. She has successfully documented and launched several new diagnostic products on the international market.

070601 Carina Schmidt new CEO of Athera

Carina Schmidt joins Athera following 7 successful years as management consultant, interim CEO and business advisor to several biotech start-ups, which has given extensive experience in development of innovative companies. She has experience from 25 years in industry, mainly in business development, international marketing and product management within the Life Science area.

070101 Per Sjöberg is appointed new Chairman of the Board

Dr. Sjöberg joined the board of directors during the fall 2006 and has broad experience in marketing of pharmaceutical products from Astra and has held several senior management positions including CEO at Perstorp Pharma, Biocarb and Camurus.

061201 Athera diagnostic test development organization strengthened

During December another test developer and design engineer has joined the Athera diagnostic development team. The team now involves 7 persons with assay development experience from Uppsala-based market leader in allergy diagnostics, Phadia. The team is currently working with validation of Athera aPC™ kits in several CVD cohorts, as well as with the development of the adequate quality systems for the planned registrations in Europe and USA .

061101 CVDIMMUNE agreements signed and projects started

The CVDIMMUNE agreement was signed and the projects initiated, for more information on the CVDImmune project please visit www.cvdimmune.com

060630 Atheras new issue of shares fully subscribed

In June, a new issue of 6.3 MSEK was completed with Karolinska Development II and Östersjöstiftelsen as co-lead investors. The funds will be used for clinical studies on the Athera aPC™ test and to advance Athera's other R&D programs.

060327 Athera-sponsored EU application CVDIMMUNE receives favourable evaluation

The CVDIMMUNE application sponsored by Athera and Karolinska Institutet was selected in fierce competition to enter the negotiation phase for funds from the 6th FP. EU's examiner commented "Overall a very good proposal, addressing important issues in CVD, with a very good potential for delivering interesting and innovative products, including new diagnostic tools for CVD markers and potential new drug candidates."

Member of

In the News

Linchpin of immune system doubles as stroke protector Published in New Scientist Health 2010-02-21

Nytt test avslöjar om du kan få stroke(in Swedish) Published in Expressen 2010-02-12

Svenska forskare föreslår nytt test för hjärt-kärlsjukdom(in Swedish) Published in Dagens Medicin 2010-02-12

Hopp om vaccin mot stroke(in Swedish) Published in Kemivärlden Biotech 2010-02-12

Hopp om vaccin mot stroke(in Swedish) Published in Mentoronline 2010-02-12

Vår renlighet kan orsaka stroke(in Swedish) Published in svt.se 2010-02-12

Member of